Acorda Therapeutics, Inc.

ACORNASDAQHealthcare

$0.66

$-0.21(-24.02%)

Market Cap$821028

P/E Ratio—

52W High$24.2

52W Low$0.6116

Avg Volume140K

Open$0.78

Beta1.46

Net Income Financials Revenue

Acorda Therapeutics, Inc. (ACOR) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

ACOR · net income · updated Jun 9, 2026

Core profitability metrics

ACOR · net income · margin · TTM · CAGR

Net income was −$252.9M for FY2023 (fiscal year ending 2023-12-31), down 283.6% year-over-year. Net profit margin was -214.9%. Based on available data, Acorda Therapeutics, Inc. has been profitable since at least 2011.

FY2023 Net Income−$252.9M▼ -283.6% YoY

Trailing 12M (TTM)−$263.4Mtrailing 4 quarters sum

Net Profit Margin-214.9%−$252.9M ÷ $117.6M

YoY Change-283.6%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2011

▸ FMP /income-statement · Annual · ACOR net income history · ACOR profit margin

Annual net income data

ACOR · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2023Loss−$252.9M▼ 283.6%-214.9%$117.6M

FY2022Loss−$65.9M▲ +36.6%-55.6%$118.6M

FY2021Loss−$104.0M▼ 4.4%-80.5%$129.1M

FY2020Loss−$99.6M▲ +63.5%-65.1%$153.0M

FY2019Loss−$273.0M▼ 910.4%-141.9%$192.4M

Net income vs peers (Healthcare)

ACOR vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Acorda Therapeutics, Inc.YOU

ACOR

−$252.9M-283.6%-214.9%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Acorda Therapeutics, Inc. (ACOR) reported net income of −$252.9M for FY2023 (fiscal year ending 2023-12-31), down 283.6% year-over-year. The net profit margin was -214.9% — meaning the company kept $-2.15 of every dollar of revenue as profit.

Based on available data, Acorda Therapeutics, Inc. has been profitable since at least 2011. Net income reached a peak of $155.0M in FY2012. Data available for 15 fiscal years.

Acorda Therapeutics, Inc.'s net profit margin was -214.9% for FY2023, based on the latest annual results.

Investors sometimes search for "Acorda Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from ACOR net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

ACOR net income · 4 questions

Acorda Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $252.9M for FY2023.

is ACOR profitabledoes ACOR make a profitACOR profitabilityACOR profitable company

▸ Source: FMP /income-statement · GAAP · Acorda Therapeutics, Inc. · Acorda Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026